oral semaglutide launch Novo Nordisk has received FDA approval for Wegovy® (semaglutide) 25 mg, taken once daily, making it the first oral GLP-1 drug approved for obesity. Based on OASIS and SELECT trials, it Hims and Novo Nordisk: Compounded

Not a medical necessity

Emerging data suggest that in the context of weight loss induced by GLP-1 medications, incorporating resistance training (rather than relying solely on aerobic or walking activity) helps preserve lean mass

On top of this, some cancer cells express receptors for GHRH itself- effectively a target for GHRH analogs like sermorelin

I may be an N of one, but the evidence is more than anecdotal

The 50 mg setup is far easier to draw accurately (20 units is a clean, mid-barrel mark) because the higher concentration and larger per-dose amount land on a bigger, more forgiving volume

Potenciacin de la Secrecin Insulnica: Tanto el GLP-1 como el GIP actan en conjunto para optimizar la respuesta insulnica, mejorando el control glucmico y reduciendo la resistencia a la insulina